Abstract：Objective To analyze the clinical efficacy of sacubitril-valsartan combined with metoprolol in the treatment of chronic heart failure. Methods A total of 115 patients with chronic heart failure were admitted from 1 January 2021 to 30 June 2022，were selected and divided into a conventional group（57 cases）and a study group（58 cases）according to odd and even numbers. The two groups were treated with different medication regimens, and the efficacy was compared.  Results The study group showed better outcomes in terms of left ventricular posterior wall thickness, left ventricular ejection fraction, left ventricular end-systolic diameter, and left ventricular end-diastolic diameter compared to the conventional group. The time to relieve symptoms such as dyspnea, fatigue, and fluid retention was shorter in the study group. The levels of lactate dehydrogenase, creatine kinase-MB, cardiac troponin I, and brain natriuretic peptide improved more significantly in the study group than in the conventional group, with statistically significant differences （t＝10.782, 10.660, 7.926, 6.992, 8.964, 10.283, 9.255, 21.650, 10.916, 16.312, 8.610, all P＜0.05）. The incidence of adverse reactions between the two groups showed no statistically significant difference（χ2＝0.171, P＞0.05）.  Conclusion Sacubitril-valsartan combined with metoprolol has a significant effect in the treatment of chronic heart failure and contributes to the recovery of cardiac function.